Cullinan Therapeutics, Inc. financial data

Symbol
CGEM on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 10 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1051% % -51%
Debt-to-equity 6.7% % 47%
Return On Equity -46% % -59%
Return On Assets -43% % -55%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60,526,128 shares 2.6%
Common Stock, Shares, Outstanding 60,244,136 shares 3%
Entity Public Float $442,200,000 USD -56%
Common Stock, Value, Issued $6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 58,337,000 shares 37%
Weighted Average Number of Shares Outstanding, Diluted 58,337,000 shares 37%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $187,402,000 USD 31%
General and Administrative Expense $54,246,000 USD 0.43%
Operating Income (Loss) $241,648,000 USD -23%
Net Income (Loss) Attributable to Parent $219,879,000 USD -31%
Earnings Per Share, Basic -2.84 USD/shares 25%
Earnings Per Share, Diluted -2.84 USD/shares 24%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $88,332,000 USD 6.4%
Cash, Cash Equivalents, and Short-term Investments $377,900,000 USD -5.3%
Assets, Current $386,756,000 USD -6.7%
Property, Plant and Equipment, Net $421,000 USD -38%
Operating Lease, Right-of-Use Asset $2,630,000 USD 58%
Other Assets, Noncurrent $297,000 USD -19%
Assets $448,374,000 USD -28%
Accounts Payable, Current $841,000 USD -50%
Accrued Liabilities, Current $36,120,000 USD 31%
Liabilities, Current $37,741,000 USD 23%
Operating Lease, Liability, Noncurrent $1,903,000 USD 124%
Liabilities $39,644,000 USD 26%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,020,000 USD
Retained Earnings (Accumulated Deficit) $588,119,000 USD -60%
Stockholders' Equity Attributable to Parent $408,730,000 USD -31%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $408,730,000 USD -31%
Liabilities and Equity $448,374,000 USD -28%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $43,155,000 USD -13%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $36,805,000 USD 184%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 60,244,136 shares 3%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $173,785,000 USD 33%
Deferred Tax Assets, Gross $174,550,000 USD 33%
Operating Lease, Liability $2,683,000 USD 25%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $218,726,000 USD -31%
Lessee, Operating Lease, Liability, to be Paid $3,125,000 USD 34%
Property, Plant and Equipment, Gross $1,390,000 USD 3.7%
Operating Lease, Liability, Current $780,000 USD -40%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,190,000 USD 36%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,029,000 USD -30%
Operating Lease, Weighted Average Discount Rate, Percent 0.118 pure 7.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $442,000 USD 143%
Lessee, Operating Lease, Liability, to be Paid, Year Three $906,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $85,763,000 USD 167%
Preferred Stock, Shares Issued 555,935 shares -14%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Preferred Stock, Shares Outstanding 555,935 shares -14%
Depreciation, Depletion and Amortization $76,000 USD 0%
Deferred Tax Assets, Net of Valuation Allowance $765,000 USD 27%
Share-based Payment Arrangement, Expense $36,040,000 USD -4.7%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%